RE-BVS – Piemonte Repository

Sfoglia per AUTORE
D'ADDA M
Collezione AOU Novara

Items : 6

Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies. in Vaccines / Vaccines (Basel). 2025 Apr 16;13(4):419. doi: 10.3390/vaccines13040419.

2025
AOU Novara

Sicuranza A; Breccia M; Iuliano F; Gugliotta G; Castagnetti F; Lunghi M; Patriarca A; Intermesoli T; Luciano L; Russo Rossi A; Rege Cambrin G; Vucinic V; Malagola M; Malato A; Abruzzese E; D'Adda M; Galimberti S; Defina M; Sammartano V; Cafarelli C; Cencini E; Cartocci A; Pacelli P; Piciocchi A; Rughini A; Niederwieser D; Bocchia M;

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2024 May;24(5):323-331. doi: 10.1016/j.clml.2024.01.008. Epub 2024 Jan 2

2024
AOU Alessandria
AOU San Luigi di Orbassano
AOU Novara

Roccaro AM; Pellizzeri S; Butturini G; Bernardi S; Farina M; Defina M; Russo Rossi A; Russo S; Romano A; Tiribelli M; De Gobbi M; Coppi MR; Corsetti MT; Sancetta R; Rosti G; Lemoli RM; Castagnetti F; Lunghi F; Crugnola M; Ferrari ML; D'Adda M; Lunghi M; Stagno F; Binotto G; Abruzzese E; Bonifacio M; Russo D; Bucelli C; Iurlo A; et alii...

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. in Cancer medicine / Cancer Med. 2021 Mar;10(5):1726-1737. doi: 10.1002/cam4.3778. Epub 2021 Feb 16.

2021
AOU Alessandria
AOU San Luigi di Orbassano
AOU Novara

De Vivo A; Baccarani M; Roccaro AM; Polverelli N; Bernardi S; Farina M; Bocchia M; Gandolfi L; Aprile L; Russo S; Russo Rossi A; Tiribelli M; Romano A; Rege Cambrin G; Coppi MR; Corsetti MT; Sancetta R; Lemoli RM; Rosti G; Castagnetti F; Lunghi F; Ferrari ML; Crugnola M; Lunghi M; Binotto G; D'Adda M; Stagno F; Abruzzese E; Bonifacio M; et alii...

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. in Cancer medicine / Cancer Med. 2019 May;8(5):2041-2055. doi: 10.1002/cam4.2087. Epub 2019 Apr 4.

2019
AOU Novara

Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D;

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. in Blood advances / Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

2019
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Soverini S; Vigneri P; Rosti G; Russo D; Saglio G; Castagnetti F; Pane F; Breccia M; Bonifacio M; Tomassetti S; Trabacchi E; Spadano R; Tiribelli M; Stagno F; Sancetta R; Sica S; Rege-Cambrin G; Rupoli S; Salvucci M; Rapezzi D; Pregno P; Palmieri F; Musolino C; Miggiano MC; Montefusco E; Melpignano A; Martino B; Marasca R; Lunghi M; et alii...

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. in Drug design, development and therapy / Drug Des Devel Ther. 2015 May 18;9:2687-94. doi: 10.2147/DDDT.S79576. eCollection 2015.

2015
AOU Novara

Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM;